Amoytop Biotech

Amoytop Biotech mainly engages in the research, development, production, and sales of recombinant proteins and their long-acting modified drugs. The company focuses on immune-related cytokine drugs as its primary R&D direction, striving to become a leader in systematic immune solutions based on cytokine drugs, providing better solutions for major diseases such as viral hepatitis and malignant tumors, as well as the field of immunotherapy. In the near future, the company will focus on the clinical cure of chronic hepatitis B and continue to make breakthroughs. Since its establishment, the company has always been committed to the field of major diseases and immunotherapy, proactively laying out and building an innovative platform covering the expression, long-acting modification, and industrialization of various protein drugs, possessing a systematized innovative biomedical capability spanning from basic research, pilot-scale research, clinical research to industrialization. Currently, the company has established a national-level enterprise postdoctoral research workstation and a national-local joint engineering research center, and is recognized as a national innovative enterprise and a national intellectual property advantage enterprise. Amoytop Biotech adheres to the concept of global market integration, focuses on the domestic market in China while actively exploring international markets. Its injectable finished products have entered more than ten countries including Southeast Asia, South America, and the Commonwealth of Independent States (CIS). Through technological innovation, scientific management, and product scale-up, the company has gradually developed into one of China’s leading international biotechnology enterprises.